Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Chinese fibromyalgia market is witnessing a surge in prevalence, with a significant portion of the population affected by this chronic pain condition. This rising prevalence is attributed to factors like changing lifestyles, increased awareness, and improved diagnostic techniques.
With the increasing number of fibromyalgia cases, there's a heightened demand for effective treatments in the Chinese market. Patients are seeking relief from symptoms such as widespread pain, fatigue, and sleep disturbances, driving the need for innovative therapeutic solutions.
In China, the treatment pattern for fibromyalgia is continuously evolving, fibromyalgia is treated holistically with both traditional treatments and alternative therapies. The traditional remedies include pain relievers, anti-depressants, and anti-seizure medications, but alternative avenues such as acupuncture, herbal remedies, and mind-body interventions are now being explored.
Even though the interest in fibromyalgia among Chinese consumers is on the rise, the industry also faces a number of challenges. The low levels of awareness that both health professionals and the public have often results in underestimation and a lack of proper direction of the condition which in most cases leads to uncontrolled progress of the disorder. However, in narrow areas, it is a question of at-home specialty care as well as high-quality treatment options availability.
Chinese patients with fibromyalgia are being offered novel treatments that either need regulation or are proved safe, in an evolving regulatory environment. Public health regulators are making efforts in optimizing approval processes for new drugs while keeping strict standards of effectiveness and safety simultaneously.
From the drug import and approval to distribution, foreign firms that would like to enter the Chinese market of fibromyalgia confront many barriers to entry. In addition to the above, launching and promoting a medical device requires developing strategies for dealing with intricate regulatory as well as business processes, acquiring cooperation by local distributors and producers, and comprehending the specific market dynamics and demands of patients.
As whole, the Chinese real fibromyalgia medicine is experiencing active research and development initiatives targeting to produce new treatment options. For this reason, investigation of TCM prescriptions (TCM), herbs and composite therapy, is important in management of fibromyalgia symptoms.
And there is notably a high tendency among medical marketing channels in the Chinese fibromyalgia market to emphasis on patients’ education and support initiatives. Among the key players are the healthcare professionals, advocacy groups, and also the pharmaceutical companies, who are continuously striving to create an awareness, run educational programs, and offer support programs for the patients and their families as well.
Despite challenges, the Chinese fibromyalgia market presents significant expansion opportunities for pharmaceutical companies and healthcare providers. With the increasing recognition of fibromyalgia as a legitimate medical condition and the growing acceptance of diverse treatment approaches, the market is ripe for innovation and growth.
Looking ahead, the Chinese fibromyalgia market is poised for continued growth and evolution. Factors such as advancements in diagnostic technologies, expanding treatment options, increasing healthcare infrastructure, and growing patient advocacy are expected to shape the future landscape of fibromyalgia management in China. As awareness continues to improve and research efforts intensify, the market is likely to witness a shift towards more personalized and comprehensive care approaches tailored to the unique needs of fibromyalgia patients in China.
Chinese Fibromyalgia Market Highlights:
Chinese Fibromyalgia Market Overview
Chinese Fibromyalgia Market Size was valued at USD 13.45 Billion in 2023. The Global Chinese Fibromyalgia industry is projected to grow from USD 13.93 Billion in 2024 to USD 21.53 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 14.32% during the forecast period (2024 - 2032).
Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than in the general population. For fibromyalgia to be diagnosed, the differential diagnosis is most commonly used. Other diagnostic procedures, such as laboratory evaluations are also used.
Notably, increasing cases of rheumatic diseases and growing geriatric population are the key factors driving the Chinese fibromyalgia market. According to the study published in Aging Clinical and Experimental Research in 2014, fibromyalgia syndrome can affect people of all age group, with the high prevalence in the elderly population as the geriatric population is more vulnerable towards pain, reduced mobility, and sleep disruption. In the general population, the prevalence of fibromyalgia increases by 2% at the age of 20 to 8% at the age of 70.
Growing awareness among the population, and rising incidences of traumatic stress and road accidents are also fueling the market growth. According to a study published in Pain Research and Management journal, in 2014, it was found that physical trauma is followed by fibromyalgia syndrome. In this study, conducted with a specific cohort of individuals involved in a motor vehicle collision, found that 8% of individuals developed widespread chronic pain. Widespread chronic pain characterizes fibromyalgia.
However, difficulty in diagnosis may hinder the growth of the market over the forecast period. Fibromyalgia can’t be easily confirmed as the condition is commonly expressed with many other accompanying chronic disorders such as rheumatic diseases, neurological disorders, mental health problems, and others
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with an extensive product portfolio and pipeline, announced positive results from its clinical pharmacokinetic (PK) bridging study of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) in healthy adult male and female ethnic Japanese and Chinese volunteers in February 2024.
A Sheffield woman who claimed to have perfect health after curing herself of chronic fatigue will appear on Dragons’ Den in January 2024. Giselle Boxer was working at one of the top advertising agencies when she was twenty-six years old; that is when M.E (myalgic encephalomyelitis) was diagnosed.
There has been massive research coverage and news about various aspects of fibromyalgia in China since July 2024. According to a recent cross-sectional study examining demography characteristics as well as clinical features among Chinese fibromyalgia patients, these studies concluded that fibromyalgia significantly affects the quality of life and is often accompanied by other health problems such as depression and chronic fatigue.
Intended Audience
- Pharmaceutical Companies
- Hospitals & Clinics
- Research and Development (R&D) Companies
- Government Research Institute
- Academic Institutes and Universities
Figure: Chinese Fibromyalgia Market by Diagnosis market share, 2016 (%)
Sources: Annual reports, Press release, White paper, Company presentation
Chinese Fibromyalgia Market Segmentat Insights
The chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of the diagnosis, the chinese fibromyalgia market is classified into laboratory evaluation and presence of central sensitization.
On the basis of the treatment, the chinese fibromyalgia market is segmented into targeted treatment and symptomatic treatment.
On the basis of the end-users, the chinese fibromyalgia market is segmented into hospitals, clinics, diagnostic centers, and others.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Key Findings
- The Chinese fibromyalgia market is expected to reach USD 3,079.1 million by 2022 at a CAGR of 18.7%
- On the basis of the diagnosis, the laboratory evaluation segment is expected to command the largest market share of 77.2% over the review period, and it is also expected to grow at the fastest CAGR of 19.1% during the forecast period 2017-2022
- On the basis of the treatment, the symptomatic treatment segment is expected to command the largest market share of 68.6% over the review period, and targeted treatment is expected to grow at the fastest CAGR of 19.2% during the forecast period 2017-2022
- South Central China holds the largest share of the Chinese fibromyalgia market and is expected to reach USD 785.3 million by 2022
- North China is the fastest growing market, which is expected to grow at a CAGR of 19.2% over the forecast period 2017-2022
Chinese Fibromyalgia Market Regional Analysis
South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.
The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e. 9.9% per year.
Chinese Fibromyalgia Market Key Players
Some of key the players in the chinese fibromyalgia market are
- Pfizer,
- Roche,
- Astellas Pharma,
- Eli Lilly and Company,
- Johnson & Johnson Services, Inc.,
- SANOFI,
- Bayer AG,
- GlaxoSmithKline,
- AstraZeneca,
- AbbVie,
- ALLERGAN,
- Boehringer Ingelheim,
- Cephalon, Inc.,
- Vertical Pharmaceuticals,
- Sunovion Pharms Inc,
- Jazz Pharmaceuticals,
- ABBOTT,
- NOVARTIS, and
- others.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
